Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFirst Affiliated Hospital Xi'an Jiaotong University
About this trial
The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:
* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins? * Will the use of UDCA decrease other adverse events in patients taking oral statins?
Participants will:
* Take Atorvastatin combined with UDCA or a placebo daily for 6 months * Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.
Eligibility criteria
Qualifiers
Age 18-75 years old.
LDL-C≥3.4mmol/l (130 mg/dL).
Glycosylated hemoglobin ≤ 6.0% (42 mmol/mol).
Voluntarily sign informed consent.
Disqualifiers
Previous diagnosis of diabetes or prediabetes.
Past or current use of hypoglycemic drugs.
Oral administration of statin lipid-lowering drugs within three months before enrollment.
Combined oral drug quantity ≥3.
Trial design
Treatments tested in this trial
- Ursodeoxycholic acid (UDCA) 500 mg
- Placebo
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov